|
Variables
|
Total (n = 205)
|
Micro-nutrient deficiency group (n = 80, 39.0%)
|
Non-deficiency group (n = 125, 61.0%)
|
P-value
|
|---|
|
Male sex
|
118 (57.6)
|
44 (55.0)
|
74 (59.2)
|
0.553
|
|
Age
|
34 (19–47)
|
27 (19–41)
|
37 (20–51)
|
0.003
|
|
The path of laboratory test
| | | |
0.150
|
|
Outpatients clinic
|
191 (93.2)
|
72 (90.0)
|
119 (95.2)
| |
|
Hospitalization patients
|
14 (6.8)
|
8 (10.0)
|
6 (4.8)
| |
|
Number of micronutrient tests
| | | | |
|
Folate
|
127 (62.0)
|
64 (80.0)
|
63 (50.4)
|
< 0.001
|
|
Vitamin B12
|
128 (62.4)
|
64 (80.0)
|
64 (51.2)
|
< 0.001
|
|
25-OH-vitamin D
|
184 (90.2)
|
67 (83.8)
|
117 (94.4)
|
0.013
|
|
Ferritin
|
97 (47.3)
|
48 (60.0)
|
49 (39.2)
|
0.004
|
|
Type of IBD
| | | |
0.003
|
|
UC
|
49 (23.9)
|
9 (11.3)
|
40 (32.0)
| |
|
CD
|
143 (69.8)
|
66 (82.5)
|
77 (61.6)
| |
|
Intestinal BD
|
13 (6.3)
|
5 (6.3)
|
8 (6.4)
| |
|
Medications
| | | | |
|
5-ASA
|
114 (55.6)
|
33 (41.3)
|
81 (64.8)
|
0.001
|
|
Steroids
|
12 (5.9)
|
3 (3.8)
|
9 (7.2)
|
0.305
|
|
Azathioprine
|
66 (32.2)
|
32 (40.0)
|
34 (27.2)
|
0.056
|
|
Anti-TNF
|
101 (49.3)
|
45 (56.3)
|
56 (44.8)
|
0.110
|
|
Methotrexate
|
33 (16.1)
|
11 (13.8)
|
22 (17.6)
|
0.464
|
|
6-MP
|
2 (1.0)
|
0 (0)
|
2 (1.6)
|
0.256
|
|
Othersa
|
12 (5.9)
|
2 (2.5)
|
10 (8.0)
|
0.102
|
|
Supplementary medications
| | | | |
|
Iron supplementation
|
77 (37.6)
|
43 (53.8)
|
34 (27.2)
|
< 0.001
|
|
Folate supplementation
|
50 (24.4)
|
26 (32.5)
|
24 (19.2)
|
0.031
|
|
Multivitamin
|
52 (25.4)
|
21 (26.3)
|
31 (24.8)
|
0.816
|
|
Calcium, Vitamin D supplementation
|
127 (62.0)
|
51 (63.7)
|
76 (60.8)
|
0.671
|
|
Vitamin B12 supplementation
|
43 (21.0)
|
30 (37.5)
|
13 (10.4)
|
< 0.001
|
|
Vitamin C supplementation
|
3 (1.5)
|
0 (0)
|
3 (2.4)
|
0.163
|
|
Zinc supplementation
|
7 (3.4)
|
3 (3.8)
|
4 (3.2)
|
0.832
|
|
Osteoporosis medication
| | | | |
|
SERM
|
3 (1.5)
|
1 (1.3)
|
2 (1.6)
|
0.839
|
|
Bisphosphonate
|
14 (6.8)
|
1 (1.3)
|
13 (10.4)
|
0.011
|
|
Operation
|
65 (31.7)
|
33 (41.3)
|
32 (25.6)
|
0.019
|
|
Underlying disease
| | | | |
|
Hypertension
|
4 (2.0)
|
1 (1.3)
|
3 (2.4)
|
0.561
|
|
Diabetes
|
1 (0.5)
|
0 (0)
|
1 (0.8)
|
0.423
|
|
Osteoporosis
|
38 (18.5)
|
13 (16.3)
|
25 (20.0)
|
0.500
|
|
Othersb
|
46 (22.4)
|
19 (23.8)
|
27 (21.6)
|
0.719
|
- Data are expressed as median (interquartile range, IQR) or n (%). *P-value for comparing patients with micronutrient deficiency group and non-deficiency group
- IBD, Inflammatory bowel disease; UC, Ulcerative colitis; CD, Crohn’s disease; BD, Behçet’s disease; 5-ASA, 5-aminosalicylic acid; anti-TNF, anti-tumor necrosis factor; 6-MP, 6-mercaptopurine; SERM, Selective estrogen receptor modulators
- aMongersen, vedolizumab
- bMyelodysplastic syndrome, Systemic lupus erythematosus, aortic valve disease, Bronchiolitis obliterans with organizing pneumonia, osteoarthritis, coronary artery occlusive disease, cancer
